Astellas Pharma EBIT

The latest EBIT for ALPMY is $420B as of June 2026. That compares with $270B in the prior-year period — up 55.4% year over year. That is above the Healthcare sector average of $22B. Investors often review this figure alongside Astellas Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALPMY's EBIT moved from $270B to $420B — a 55.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Astellas Pharma's operating scale or balance-sheet position.

Against Healthcare companies, ALPMY currently prints $420B for EBIT, while the sector average sits near $22B. That is roughly 1788.5% above the sector mean. Large gaps often invite a closer look at Astellas Pharma's growth, margins, and balance sheet.

A EBIT figure of $420B for ALPMY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting ALPMY's EBIT ($420B), review year-over-year change from $270B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.